Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

309.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
51 52 Next >
What Is the Dividend Payout for Amgen Stock?
Amgen offers a packed pipeline and healthy dividend distributions. 
Via The Motley Fool
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Revenue is climbing at these two drug companies -- and the trend should continue. 
Via The Motley Fool
3 Dividend Growth Stocks to Buy and Hold
What's better than a dividend? A dividend that's growing. 
Via The Motley Fool
Stock Market Shifts Toward Small Caps After Tame CPI; JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review
Megacaps and chip plays tumbled Thursday, but mostly still have healthy charts. 
Via Investor's Business Daily
Check Out What Whales Are Doing With AMGN
Via Benzinga
What the Options Market Tells Us About Amgen
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
TSLA Hit Our Target - Here’s What’s Next
We’ll look at another big mover right now: precious metals. They still look good after Fed Chair Jerome Powell tried to talk down rate cuts today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
3 Small-Cap Stocks With Explosive 2X Growth Potential
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
Amgen Unusual Options Activity
Via Benzinga
Can Amgen Stock Keep Trouncing the S&P 500?
Amgen's market-beating ways are unlikely to evaporate any time soon. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Dividend Stocks Crushing the S&P 500 With 30%+ Annual Total Returns
With technology growth stocks propelling the S&P 500, dividend stocks have often found themselves playing catch-up. But not these three. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... 
Via Talk Markets
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Smart Money Is Betting Big In AMGN Options
Via Benzinga
Amgen, Inc. Dividend Stock Analysis
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis. 
Via Talk Markets
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better. 
Via The Motley Fool
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
1 Dividend Growth Stock to Buy and Hold for 10 Years
This company's payouts look safe. 
Via The Motley Fool
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe. 
Via Talk Markets
These Are The Best Dow Jones Stocks Of 2024 Thus Far
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Tech Is Consolidating And The Market’s Seeking New Leadership
The tape tells the tale, just like it always does: The tech sector is clearly in consolidation mode right now. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.